<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00585013</url>
  </required_header>
  <id_info>
    <org_study_id>CHECP1</org_study_id>
    <nct_id>NCT00585013</nct_id>
  </id_info>
  <brief_title>Inhaled NO as an Anti-inflammatory and Anti-reperfusion Agent in Infants and Children Undergoing Cardiopulmonary Bypass</brief_title>
  <official_title>A Trial of Inhaled Nitric Oxide (NO) as an Anti-Inflammatory and Anti-Reperfusion Agent in the Treatment of Infants and Children Undergoing Cardiopulmonary Bypass for Repair of Congenital Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Each year, there are over 400,000 cardiac surgical operations performed in the United States;
      of which 10,000 are performed on children. These operations are made possible by the use of
      the heart-lung bypass machine, also known as cardiopulmonary bypass. This machine allows for
      the body to be supported while the heart is repaired. While this machine has been life
      saving, it has risks and can lead to a variety of complications.

      One such complication results from the fact that the patient's blood is exposed to the
      foreign material of the machine, such as plastic tubing. In nearly all cases of cardiac
      surgery, this leads to a whole body response in the patient following the operation. This
      response, inflammation, is characterized by alterations in the function of the heart and
      lungs, fever, fluid retention, and bleeding disorders in the postoperative period. While this
      is usually temporary and self limiting, significant morbidity occurs in approximately 1-2% of
      cases where this inflammatory response is present. Additionally, children appear to be more
      susceptible to this response. This can lead to significant postoperative complications that
      are not associated with the actually surgical procedure performed on the heart.

      The exact cause of this response is not fully understood. However, it is important to
      understand the triggers, timing, and pattern of this complex inflammatory response in order
      to modify or arrest it. Unlike other situations associated with this type of whole-body
      inflammatory reaction such as trauma or overwhelming infection, cardiac surgical teams have
      the advantage of knowing when the trigger will occur (i.e. during the cardiac operation) and
      hence have the opportunity for preemptive intervention in an effort to minimize the response.
      One such effort is the focus of this proposal.

      Nitric oxide (NO) is a gas that has been used for years in the treatment of lung disease in
      infants. It has been life saving and safe. Recently, it has been investigated for its
      anti-inflammatory effects outside the lungs. We propose delivering NO to the source of the
      greatest inflammation in cardiac surgery, the cardiopulmonary bypass machine. It is our
      intention to show that in doing so; we can minimize the inflammation found in the first 24
      hours following cardiac surgery in children. If we are correct, the reduction of this
      inflammation will result in less damage to other organs of the child's body and improved
      outcome following surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      I. Hypothesis

      Treatment of children during surgery employing cardiopulmonary bypass with inhaled, exogenous
      nitric oxide (iNO) delivered to the cardiopulmonary bypass circuit will:

        1. Modulate ischemia/reperfusion injury

        2. Influence endothelial dysfunction

        3. Ameliorate the bypass-triggered systemic inflammatory response

      II. Specific Aims

      Three specific aims will test this hypothesis:

      Delivery of iNO to the cardiopulmonary bypass circuit will result in a decrease in:

        1. Measures of end-organ dysfunction often associated with CPB; pulmonary function, cardiac
           injury markers, serum creatinine, and neurologic injury markers.

        2. Measures of inflammatory response, specifically IL-6 and TNFa via its antioxidant
           properties.

        3. Platelet activation and aggregation leading to reduced transfusion requirements.

      III. Introduction and Background

        -  Cardiopulmonary bypass leads to ischemia/reperfusion injury. One of the mediators of
           this injury is oxygen radical production. NO is known to bind oxygen radical species.

        -  Cardiopulmonary bypass leads to endothelial dysfunction. This is mediated through
           cell-free hemoglobin binding endogenous NO, as seen in sickle cell disease.

        -  Both of these factors, separately and in combination, perpetuate the inflammatory
           response triggered by CPB. NO affects this response by interfering with this process.
           Additionally, NO is known to affect neutrophil chemotaxis as well as platelet activation
           and aggregation, both of which further amplify the inflammatory response.

      IV. Basic Protocol Experimental Design In a prospective, randomized, controlled, blinded
      pilot trial we will compare 20 ppm of iNO delivered to the CPB circuit. Our study will target
      children undergoing cardiopulmonary bypass (CPB) for surgery for the correction of
      transposition of great arteries (TGA) and Tetralogy of Fallot (TOF).

      Subjects Inclusion Undergoing repair of TGA and TOF &lt; 16 years of age Exclusion Age &gt; 16
      years of age Pregnancy Known bleeding disorder

      Treatment Protocol Following informed consent, blood will be drawn pre-operatively for
      baseline characteristics (methemoglobin, venous saturation, CBC, S100, gene expression
      profiles, BNP, cTnI, IL-6, IL-8, lactate, TNFalpha)[Table, Blood sample for Study].
      Intra-operatively we will use a standardized anesthetic protocol unless contraindicated by
      specific patient clinical characteristics. Intraoperative measurements will include: aortic
      cross clamp time, and total cardiopulmonary bypass time. Intraoperative hemodynamic
      measurements will include: mean systemic blood pressure (MAP), central venous pressure, right
      atrial pressure pulmonary artery pressure, and pulmonary capillary wedge pressure (when
      available). Blood samples will be drawn following CPB upon arrival to the ICU and will be
      analyzed as above. Repeat blood samples for each will be drawn again after 12, 24, and 48
      hours. Patients will be followed to the time of discharge. Ventilator settings, length of ICU
      and hospital stay will be recorded. All measurements in both groups will be the same. Time
      points will be referenced from the time of admission to the PICU for both groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Inflammatory Mediators Post CPB</measure>
    <time_frame>48 hours</time_frame>
    <description>Inflammation measured through the measurement inflammatory mediators, serum interleukin-6, serum interleukin-8, and tumor necrosis factor. Baseline (preoperative, 0h, 12h, 24h, and 48h.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial Injury</measure>
    <time_frame>48 hours</time_frame>
    <description>Troponin levels correlate with myocardial injury. Greater troponin levels represent greater myocardial injury</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial Function as Measured by B-type Natiuretic Peptide (BNP) Levels</measure>
    <time_frame>48 hours</time_frame>
    <description>BNP levels correlate to ventricular and myocardial performance, function, and strain. Higher values represent greater strain and decreased function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ischemic Injury as Measured by Lactate Levels</measure>
    <time_frame>48 hours</time_frame>
    <description>Lactate levels correlate to ischemic injury. Higher values represent more injury.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Methhemoglobin &gt;5%, Gene Expression Profiles, and S100B.</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>Nitric Oxide Delivery Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Placebo delivery of oxygen at standard dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide</intervention_name>
    <description>Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.</description>
    <arm_group_label>Nitric Oxide Delivery Group</arm_group_label>
    <other_name>NO gas</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the following congenital heart lesions who require cardiopulmonary
             bypass for surgical repair or palliation will be eligible:

          -  D-transposition of the great vessels (D-TGA)

          -  Tetralogy of Fallot (TOF)

          -  Children of age less than 16 years

        Exclusion Criteria:

          -  Signs of persistently elevated pulmonary vascular resistance preoperatively

          -  Cardiac arrest one week prior to surgery

          -  Prior surgical procedure that required use of cardio-pulmonary bypass

          -  Acute or chronic infection such as sepsis or wound infections

          -  History of any pulmonary condition such as pneumonia or respiratory distress syndrome

          -  Patients that have received steroid treatment within the last month

          -  DiGeorge syndrome

          -  Active bleeding disorder

          -  Any other condition associated with non-cardiac morbidity

          -  Use of another investigational drug

          -  Age over 16 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Checchia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2008</study_first_posted>
  <results_first_submitted>December 19, 2012</results_first_submitted>
  <results_first_submitted_qc>November 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2015</results_first_posted>
  <last_update_submitted>November 3, 2015</last_update_submitted>
  <last_update_submitted_qc>November 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inhaled Nitric Oxide (NO)</keyword>
  <keyword>Anti-inflammatory</keyword>
  <keyword>Anti-reperfusion agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were randomized by the research perfusionist using sequentially ordered randomization codes. The randomization codes were generated using a computerized random number generator. The entire care team was blinded to the delivery device and drug delivery. Only the study perfusionist was aware of randomization and delivery.</recruitment_details>
      <pre_assignment_details>Seventeen patients consented and were enrolled in the study. There were eight consent failures. One patient was disqualified after consent and randomization due to intraoperative findings of a lesion inconsistent with preoperative diagnosis and change in operative plan.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 Treatment</title>
          <description>Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
Nitric Oxide : Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.</description>
        </group>
        <group group_id="P2">
          <title>2 Placebo</title>
          <description>Placebo delivery of oxygen at standard dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 Treatment</title>
          <description>Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
Nitric Oxide : Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.</description>
        </group>
        <group group_id="B2">
          <title>2 Placebo</title>
          <description>Placebo delivery of oxygen at standard dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value=".4" spread=".1"/>
                    <measurement group_id="B2" value=".4" spread=".1"/>
                    <measurement group_id="B3" value=".4" spread=".1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Inflammatory Mediators Post CPB</title>
        <description>Inflammation measured through the measurement inflammatory mediators, serum interleukin-6, serum interleukin-8, and tumor necrosis factor. Baseline (preoperative, 0h, 12h, 24h, and 48h.</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nitric Oxide Delivery Group</title>
            <description>Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
Nitric Oxide: Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo delivery of oxygen at standard dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Inflammatory Mediators Post CPB</title>
          <description>Inflammation measured through the measurement inflammatory mediators, serum interleukin-6, serum interleukin-8, and tumor necrosis factor. Baseline (preoperative, 0h, 12h, 24h, and 48h.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Interleukin-6 Preoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="3.5"/>
                    <measurement group_id="O2" value="3.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin-6, 0 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" spread="44.6"/>
                    <measurement group_id="O2" value="78.3" spread="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin-6, 12 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" spread="38.7"/>
                    <measurement group_id="O2" value="73.3" spread="67.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin-6, 24 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2" spread="28.4"/>
                    <measurement group_id="O2" value="80.7" spread="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin-6, 48 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2" spread="30.6"/>
                    <measurement group_id="O2" value="39.4" spread="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin-8, Preoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9" spread="28.8"/>
                    <measurement group_id="O2" value="39.8" spread="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin-8, 0 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.8" spread="104.1"/>
                    <measurement group_id="O2" value="248.9" spread="191.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin-8, 12 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" spread="133.4"/>
                    <measurement group_id="O2" value="85.9" spread="59.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin-8, 24 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.5" spread="62.7"/>
                    <measurement group_id="O2" value="139.2" spread="162.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin-8, 48 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.2" spread="107.0"/>
                    <measurement group_id="O2" value="60.4" spread="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor Necrosis Factor Preoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="0.8"/>
                    <measurement group_id="O2" value="3.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor Necrosis Factor, 0 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.5"/>
                    <measurement group_id="O2" value="4.1" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor Necrosis Factor, 12 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.07"/>
                    <measurement group_id="O2" value="1.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor Necrosis Factor, 24 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.3"/>
                    <measurement group_id="O2" value="3.2" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor Necrosis Factor, 48 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.09"/>
                    <measurement group_id="O2" value="2.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>This p value applies to all time points for all variables.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Myocardial Injury</title>
        <description>Troponin levels correlate with myocardial injury. Greater troponin levels represent greater myocardial injury</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Treatment</title>
            <description>Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
Nitric Oxide : Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.</description>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
            <description>Placebo delivery of oxygen at standard dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Injury</title>
          <description>Troponin levels correlate with myocardial injury. Greater troponin levels represent greater myocardial injury</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.07"/>
                    <measurement group_id="O2" value="0.06" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6" spread="37.8"/>
                    <measurement group_id="O2" value="54.1" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="3.2"/>
                    <measurement group_id="O2" value="15.9" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="2.6"/>
                    <measurement group_id="O2" value="12.5" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="1.6"/>
                    <measurement group_id="O2" value="7.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>This applies for measurements at preoperative and 0 h time points.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>This applies to measurements at time points 12 h, 24 h, and 48 h.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Myocardial Function as Measured by B-type Natiuretic Peptide (BNP) Levels</title>
        <description>BNP levels correlate to ventricular and myocardial performance, function, and strain. Higher values represent greater strain and decreased function.</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Treatment</title>
            <description>Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
Nitric Oxide : Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.</description>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
            <description>Placebo delivery of oxygen at standard dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Function as Measured by B-type Natiuretic Peptide (BNP) Levels</title>
          <description>BNP levels correlate to ventricular and myocardial performance, function, and strain. Higher values represent greater strain and decreased function.</description>
          <units>pg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="22"/>
                    <measurement group_id="O2" value="100" spread="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" spread="34"/>
                    <measurement group_id="O2" value="94" spread="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="494" spread="222"/>
                    <measurement group_id="O2" value="812" spread="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="425" spread="154"/>
                    <measurement group_id="O2" value="938" spread="511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="558" spread="535"/>
                    <measurement group_id="O2" value="1298" spread="827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>This applies to measurements at preoperative, 0 h, and 48 h time points.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>This applies to time points at 12 h and 24 h.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ischemic Injury as Measured by Lactate Levels</title>
        <description>Lactate levels correlate to ischemic injury. Higher values represent more injury.</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Treatment</title>
            <description>Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
Nitric Oxide : Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.</description>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
            <description>Placebo delivery of oxygen at standard dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemic Injury as Measured by Lactate Levels</title>
          <description>Lactate levels correlate to ischemic injury. Higher values represent more injury.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.2"/>
                    <measurement group_id="O2" value="0.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.6"/>
                    <measurement group_id="O2" value="1.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.4"/>
                    <measurement group_id="O2" value="1.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.5"/>
                    <measurement group_id="O2" value="1.4" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.2"/>
                    <measurement group_id="O2" value="1.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Applies to all time points.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Methhemoglobin &gt;5%, Gene Expression Profiles, and S100B.</title>
        <time_frame>48 hours</time_frame>
        <population>Data not collected for these assessments</population>
        <group_list>
          <group group_id="O1">
            <title>1 Treatment</title>
            <description>Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
Nitric Oxide : Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.</description>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
            <description>Placebo delivery of oxygen at standard dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Methhemoglobin &gt;5%, Gene Expression Profiles, and S100B.</title>
          <population>Data not collected for these assessments</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the hospital admission or to 30 days postoperative; whichever is longer.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1 Treatment</title>
          <description>Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
Nitric Oxide : Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.</description>
        </group>
        <group group_id="E2">
          <title>2 Placebo</title>
          <description>Placebo delivery of oxygen at standard dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul Checchia MD</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>832-826-5011</phone>
      <email>checchia@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

